Capital Flow Monitor · Sponsors · CIK 1968822
Volastra Therapeutics, Inc.
1361 AMSTERDAM AVENUE, NEW YORK, NY, 10027 · 646-344-1248
Pharmaceuticals · Corporation· inc. DELAWARE true
Fit score
—
Offering
$30.1M
Sold
$30.1M
% sold
100.0%
Investors
11
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-09-23 | D ·current | 506(b) | $30.1M | $30.1M | 100.0% | 11 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Ellie McGuire — Director, NEW YORK, NY
- Jill Goldstein — Director, NEW YORK, NY
-
Luc Dochez — Director, NEW YORK, NY
1 other raise
- QurAlis Corp $20.0M of $24.9M · 80.1%
- Arjun Balar — Director, NEW YORK, NY
- Samuel Bakhoum — Director, NEW YORK, NY
- David Southwell — Executive Officer / Director, NEW YORK, NY
-
David Nicholson — Director, NEW YORK, NY
1 other raise
- Rapalogix Health, Inc. $19.1M of $25.0M · 76.5%
- Sandra Peterson — Director, NEW YORK, NY
-
Robert Mittendorff — Director, NEW YORK, NY
3 other raises
- Numerion Labs, Inc. $19.8M of $35.0M · 56.6%
- Solve Therapeutics, Inc. $48.2M of $120.5M · 40.0%
- Capital Rx, Inc. $230.8M of $232.9M · 99.1%
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.